Publications Dr. Andreas Roidl

Papers

Isert L, Mehta A, Loiudice G, Oliva A, Roidl A, Merkel OM (2023) An In Vitro Approach to Model EMT in Breast Cancer, Int J Mol Sci 2023 Apr 24;24(9):7757
Köhler B, Dubovik S, Hörterer E, Wilk U, Stöckl JB, Tekarslan-Sahin H, Ljepoja B, Paulitschke P, Fröhlich T, Wagner E, Roidl A (2022) Combating drug resistance by exploiting miRNA-200c-controlled phase II detoxification, Cancers (Basel). 2022 Nov 11;14(22):5554
von Schirnding, C., Giopanou, I., Hermawan, A., Wehl, L., Ntaliarda, G., Illes, B., Datz, S., Geisslinger, F., Bartel, K., Sommer, A.K., Lianou, M., Weiß, V., Feckl, J., Vollmar, A.V., Bräuchle, C., Stathopoulos, G. T., Wagner, E., Roidl, A., Bein, T., Engelke, H. (2021) Synergistic Combination of Calcium and Citrate in Mesoporous Nanoparticles Targets Pleural Tumors. Chem 7 (2), 480-494
Ljepoja B, Schreiber C, Gegenfurtner FA, García-Roman J, Köhler B, Zahler S, Rädler JO, Wagner E, Roidl A (2019) Inducible microRNA-200c decreases motility of breast cancer cells and reduces filamin A, PLoS One. 2019 Nov 20;14(11):e0224314
Sommer, A.K., Falcenberg, M., Ljepoja, B., Fröhlich, T., Arnold, G.J., Wagner, E., Roidl, A. (2019) Downregulation of GRK5 hampers the migration of breast cancer cells, Sci Rep. 2019 Oct 29;9(1):15548
Ljepoja, B., García-Roman, J., Sommer, A.K., Wagner, E., Roidl, A. (2018) MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators, Breast. 2019 Feb;43:31-38
Sommer, A.K., Hermawan, A., Ljepoja, B., Fröhlich, T., Arnold, G.J., Wagner, E., Roidl, A. (2018) A proteomic analysis of chemoresistance development via sequential treatment with doxorubicin reveals novel players in MCF‑7 breast cancer cells, Int J Mol Med. 2018 Oct;42(4):1987-1997
Ljepoja B, García-Roman J, Sommer AK, Fröhlich T, Arnold GJ, Wagner E, Roidl A. (2018) A proteomic analysis of an in vitro knock-out of miR-200c, Sci Rep. 2018 May 2;8(1):6927
Sommer, A.-K., Hermawan, A., Mickler, F.M., Ljepoja, B., Knyazev, P., Bräuchle, C., Ullrich, A., Wagner, E., Roidl, A. (2016) Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases, Oncotarget. 2016 Aug 2;7(31):50461-50476
Müller, K., Klein, P.M., Heissig, P., Roidl, A., Wagner, E. (2016) EGF receptor targeted lipo-oligocation polyplexes for antitumoral siRNA and miRNA delivery, Nanotechnology. 2016 Nov 18;27(46):464001
Schreiber, C., Segerer, F.J., Wagner, E., Roidl, A., Rädler, J.O. (2016) Ring-Shaped Microlanes and Chemical Barriers as a Platform for Probing Single-Cell Migration, Sci Rep. 2016 May 31;6:26858
Hermawan, A., Wagner, E., Roidl, A. (2016) Consecutive salinomycin treatment reduces doxorubicin resistance of breast tumor cells by diminishing drug efflux pump expression and activity. Oncol Rep. 2016 Mar;35(3):1732-40
Kopp, F., Hermawan, A., Oak, P.S., Ulaganathan, V.K., Herrmann, A., Elnikhely, N., Thakur, C., Xiao, Z., Knyazev, P., Ataseven, B., Savai, R., Wagner, E., Roidl, A. (2014) Sequential Salinomycin Treatment Results in Resistance Formation through Clonal Selection of Epithelial-Like Tumor Cells, Transl Oncol. 2014 Dec;7(6):702-11
Kubisch R, Fröhlich T, Arnold GJ, Schreiner L, von Schwarzenberg K, Roidl A, Vollmar AM, Wagner E (2014) V-ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo, Int J Cancer. 2014 May 15;134(10):2478-88
Kopp F, Wagner E, Roidl A (2014) The proto-oncogene KRAS is targeted by miR-200c, Oncotarget. 2014 Jan;5(1):185-95

Kopp F, Hermawan A, Oak PS, Herrmann A, Wagner E, Roidl A (2014) Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration, Mol Cancer. 2014 Jan 27;13:16

Kopp F, Schnoedt M, Haase R, Wagner E, Roidl A*, Ogris M . (2013) De-targeting by miR-143 decreases unwanted transgene expression in non-tumorigenic cells, Gene Ther. 20, 1104-1109
Kubisch R, Meissner L, Krebs S, Blum H, Günther M, Roidl A, Wagner E. (2013) A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy,Transl Oncol. 2013 Feb;6(1):1-9. Epub 2013 Feb 1
Kopp F, Oak PS, Wagner E, Roidl A.* (2012) miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression.,PLoS One. 2012;7(11):e50469. doi: 10.1371/journal.pone.0050469. Epub 2012 Nov 29
Oak, P. S., Kopp, F., Thakur, C., Ellwart, J. W., Rapp, U. R., Ullrich, A., Wagner, E., Knyazev, P., Roidl, A.* (2012) Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells, IJC International Journal of Cancer 2012 Dec 15;131(12):2808-19. doi: 10.1002/ijc.27595. Epub 2012 May 21.
Roidl, A., Foo, P., Wong, W., Mann, C., Bechtold, S,, Berger, H.J., Streit, S., Ruhe, J.E., Hart, S., Ullrich, A, Ho, H.K. (2010) The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells, Oncogene. 2010 Mar 11;29(10):1543-52
Roidl, A., Berger, H- J., Kumar, S., Bange, J., Knyazev, P., Ullrich, A. (2009) Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation, Clin Cancer Res 2009 Mar 15;15(6):2058-66. Epub 2009 Feb 24
Angermayr, M., Roidl, A., Bandlow, W. (2002) Yeast Rio1p is the founding member of a novel subfamily of protein serine kinases involved in the control of cell cycle progresssion, Mol Microbiol. 2002 Apr;44(2), 309- 324

Reviews

Ogris M, Roidl A.*(2013) Targeted therapy of cancer stem cells: science or fiction., Ther Deliv. 2013 Feb;4(2):135-8. doi: 10.4155/tde.12.153
Hart S, Gschwind A, Roidl A, Ullrich A. Book Editor: Schneider, MP (2003) CHEMICAL PROBES IN BIOLOGY: SCIENCE AT THE INTERFACE OF CHEMISTRY, BIOLOGY AND MEDICINE , Book Series: NATO SCIENCE SERIES, SERIES II: MATHEMATICS, PHYSICS AND CHEMISTRY Volume: 129 Pages: 93-103 Published: 2003

Patents

Roidl, A., Berger, H- J., Ullrich, A. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs

Posters

miR-200c regulates cell cycle, proliferation and migration in cancer cells by targeting the proto-oncogene KRAS, Florian Koop, Ernst Wagner and Andreas Roidl, Keystone Symposia “Noncoding RNAs in Development and Cancer” Vancouver, BC, Canada (January 2013)
miR-143 dependent transgene expression for cancer gene therapy, Florian Kopp, Maria Schnödt, Rudolf Haase, Ernst Wagner, Manfred Ogris and Andreas Roidl, Deutsche Gesellschaft für Gentherapie; Jahrestagung 2012 Frankfurt, Germany (March 2012)
Salinomycin as an effective drug in combinatorial treatment of breast carcinoma, Prajakta Oak, Florian Kopp, Joachim Ellwart, Axel Ullrich, Ernst Wagner, Pjotr Knyazev and Andreas Roidl, AACR Special Conference Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications San Francisco, CA, USA (October 2011)

* Correspondence author